Ann: Global Phase 3 Trial of Presendin to Launch in Q4 2021, page-98

First 98 Last

Share
Profile

Follow
Titans19

2,962 Posts.

1324

08/11/21

14:25

Post #: 57398881
Share

Originally posted by JabraD: ↑

cleared up with Tom, thought Id share:

Running another Phase 2 study is unnecessary and will delay things because we know this drug lowers ICP (as it follows the science) and moreover, the regulator (EMA) was ok with a single Phase 3 to register this drug. Running a 100 patient Phase 2 over the next say 2+ years would only re-confirm what we’ve done and not have the statistical power to show a difference in those clinical measures. So it would be a waste of time and money. As we spoke about, we are fully funded to complete, report and file Presendin for approval in these markets. If it fails, we would still retain sufficient funds to consider next steps. Unfortunately, this is biotech – we need to spend the money to find the answer(s). If it works, the payback is enormous, naturally.
An interim analysis will significantly compromise the final analysis and the strong advice from study statisticians was to not consider it.

Interim analyses introduce the chance of falsely rejecting the null hypothesis. In other words, every time you look at the data there is a chance of a type 1 error (false positive). Also the medical fraternity will likely frown on interim analysis ahead of the final planned results.

Interim analyses are more common in diseases like cancer where the intervention may be very effective, and because there is a risk of dying of progressive disease, may be unethical to not offer the intervention to the control arm. In Invex’s case, the treatment period is relatively short (24 weeks) and IIH does not pose a significant risk of death

Expand

They seem like pretty fair responses...

In your next email can you ask what their opinion of the share price is? Being this low going into a fully funded Phase 3 trial is ridiculous!

Ask for the opinion on why this may be the case? Not enough exposure to retail market? Not a headline condition?.. And what they plan to do for current holders over the next 12+ months while the trial is in progress?

If it doesn't jump soon, there is no incentive to hold when money can be made elsewhere (or sheds built...)

Cheers

IXC Price at posting: 66.0¢ Sentiment: None Disclosure: Held
3 Upvote

0 Great analysis

Reply

Top Stories

3DA

To make modern missiles, you need 3D Printing. And in that gold rush, Amaero is selling shovels

HAS

Yangibana 33% complete says Hastings, as it provides clarification on funding

BIO

Biome reaches intellectual property milestone in strain development program

RSG

HotCopper reacts as Resolute Mining told to pay US$160M if it wants its CEO back

RCE

Recce scores $6.75M R&D rebate

First 98 Last

Add IXC (ASX) to my watchlist

(20min delay)
Last 8.0¢		Change 0.000(0.00%)		Mkt cap ! $6.012M

Open	High	Low	Value	Volume
0.0¢	0.0¢	0.0¢	$0	0

Buyers (Bids)

No.	Vol.	Price($)
1	2	8.2¢

Sellers (Offers)

Price($)	Vol.	No.
9.9¢	5000	1

View Market Depth

No.	Vol.	Price($)
1	2	0.082
1	84879	0.076
1	500000	0.040
1	70001	0.036
1	100001	0.035

Price($)	Vol.	No.
0.099	5000	1
0.100	3500	1
0.150	713	1
0.000	0	0
0.000	0	0

Last trade - 16.12pm 14/11/2024 (20 minute delay)

IXC (ASX) Chart

Day chart unavailable

Ann: Global Phase 3 Trial of Presendin to Launch in Q4 2021, page-98

To make modern missiles, you need 3D Printing. And in that gold rush, Amaero is selling shovels

Yangibana 33% complete says Hastings, as it provides clarification on funding

Biome reaches intellectual property milestone in strain development program

HotCopper reacts as Resolute Mining told to pay US$160M if it wants its CEO back

Recce scores $6.75M R&D rebate

Featured News

Buyers (Bids)

Sellers (Offers)

Featured News

Ann: Global Phase 3 Trial of Presendin to Launch in Q4 2021, page-98

Top Stories

To make modern missiles, you need 3D Printing. And in that gold rush, Amaero is selling shovels

Yangibana 33% complete says Hastings, as it provides clarification on funding

Biome reaches intellectual property milestone in strain development program

HotCopper reacts as Resolute Mining told to pay US$160M if it wants its CEO back

Recce scores $6.75M R&D rebate

Featured News

Buyers (Bids)

Sellers (Offers)

Featured News